The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Clopidogrel 1A Pharma clopidogrel Generic | Acino Pharma GmbH | Peripheral Vascular Diseases | 🇪🇺 EU 2009-07-28 | Order → |
| Clopidogrel Acino clopidogrel Generic | Acino AG | Peripheral Vascular Diseases; Acute Coronary Syndrome; Myocardial Infarction; Stroke | 🇪🇺 EU 2009-07-28 | Order → |
| Clopidogrel Hexal clopidogrel Generic | Acino Pharma GmbH | Peripheral Vascular Diseases; Acute Coronary Syndrome; Myocardial Infarction; Stroke | 🇪🇺 EU 2009-07-28 | Order → |
| Clopidogrel ratiopharm GmbH clopidogrel Generic | Archie Samiel s.r.o. | Peripheral Vascular Diseases; Acute Coronary Syndrome; Myocardial Infarction; Stroke | 🇪🇺 EU 2009-07-28 | Order → |
| Clopidogrel Teva (hydrogen sulphate) clopidogrel Generic | Teva Pharma B.V. | Acute Coronary Syndrome; Peripheral Vascular Diseases; Myocardial Infarction; Stroke | 🇪🇺 EU 2009-07-27 | Order → |
| Grepid clopidogrel Generic | Pharmathen S.A. | Peripheral Vascular Diseases; Stroke; Myocardial Infarction | 🇪🇺 EU 2009-07-27 | Order → |
| Topotecan Actavis topotecan Generic | Actavis Group PTC ehf | Uterine Cervical Neoplasms; Small Cell Lung Carcinoma | 🇪🇺 EU 2009-07-24 | Order → |
| Vedrop tocofersolan Exceptional circumstancesAdditional monitoring | Recordati Rare Diseases | Cholestasis; Vitamin E Deficiency | 🇪🇺 EU 2009-07-23 | Order → |
| Clopidogrel DURA clopidogrel Generic | Mylan dura GmbH | Peripheral Vascular Diseases; Stroke; Myocardial Infarction | 🇪🇺 EU 2009-07-21 | Order → |
| Instanyl fentanyl | Istituto Gentili S.r.l. | Pain; Cancer | 🇪🇺 EU 2009-07-20 | Order → |
| Peyona (previously Nymusa) caffeine | Chiesi Farmaceutici SpA | Apnea | 🇪🇺 EU 2009-07-02 | Order → |
| Ribavirin Teva Pharma B.V. ribavirin Generic | Teva B.V. | Hepatitis C, Chronic | 🇪🇺 EU 2009-07-01 | Order → |
| Victoza liraglutide | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2009-06-30 | Order → |
| Repaglinide Teva repaglinide Generic | Teva Pharma B.V. | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2009-06-28 | Order → |
| Iressa gefitinib | AstraZeneca AB | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2009-06-24 | Order → |
| Pantecta Control pantoprazole | Takeda GmbH | Gastroesophageal Reflux | 🇪🇺 EU 2009-06-12 | Order → |
| Somac Control pantoprazole | Takeda GmbH | Gastroesophageal Reflux | 🇪🇺 EU 2009-06-12 | Order → |
| Controloc Control pantoprazole | Takeda GmbH | Gastroesophageal Reflux | 🇪🇺 EU 2009-06-11 | Order → |
| Pantoloc Control pantoprazole | Takeda GmbH | Gastroesophageal Reflux | 🇪🇺 EU 2009-06-11 | Order → |
| Pantozol Control pantoprazole | Takeda GmbH | Gastroesophageal Reflux | 🇪🇺 EU 2009-06-11 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.